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Abstract
Hepatitis B is one of the killer diseases and distributed globally. Nepal sand-
wiched between India and China. China is the country with high prevalence of 
hepatitis B surface antigen (HBsAg) account 30% of the world’s HBsAg carriers, 
and India which has intermediate HBsAg prevalence accounts 10% of the world’s 
carriers. Nepal has a low prevalence (around 1%) of hepatitis B virus (HBV) infec-
tion in general population. A and D genotypes are more prevalent in India, while 
band C is in China. The survey done in 2012 elaborated the common genes that are 
A and D and recombinant C/D in Nepal, but the clinical consequences are unclear. 
The prevalence of hepatitis B is low in Nepal, but it is widely common in intrave-
nous drug users, PLHA, and HCV positive. The implication of HBV genotyping 
has clinical implication for the treatment. Basically, response of peginterféron, and 
antiviral drugs (adefovir, lamivudine, telbivudine) in hepatitis B.
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1. Introduction
About 257 million people were infected chronically with hepatitis B (HBsAg 
positive), and 887,000 deaths were recorded in 2015 due to hepatitis B virus (HBV)-
related liver diseases, mostly from complication with cirrhosis and hepatocellular 
carcinoma (HCC) indicating an urgent necessity for better ways to prevent such 
complication of HBV [1]. HBV infection is the tenth leading cause of death and main 
contributor of HCC, which is ranked the fifth leading cause of cancer in man [2, 3]. 
HBV can be differentiated from other hepatitis viruses by genotype and subgeno-
type. HBV sequence differs by >8% form other genotypes and 4–8% nucleotide 
differences for subgenotypes. Including newly identified genotypes I and J, there are 
10 genotypes A–J. Some HBV genotypes are further classified into subgenotypes.
About 30 subgenotypes are available till date. Many studies have reported that 
different genotypes and subgenotypes show different geographical distribution and 
are related to disease progression, clinical progression, response to antiviral treat-
ment, and prognosis [4].
As shown in Figure 1, genotype A is widespread in sub-Saharan Africa, Northern 
Europe, and Western Africa; genotypes B and C are common in Asia; genotype 
C is primarily observed in Southeast Asia and China; genotype D is dominant in 
Africa, Europe, Mediterranean countries, and India including Nepal. Genotype E is 
dominant in South Africa. As a minor genotype, genotype G is reported in France, 
Germany, and the United States; and genotype H is commonly encountered in 
Hepatitis B and C
2
Central and South America and genotype I in Vietnam and Laos. The newest HBV 
genotype, genotype J, has been identified in the Ryukyu Islands in Japan [5].
However, geographical distribution is still incomplete as data was based on very 
small numbers of patients and from only few countries.
Nepal is sandwiched between India and China, two countries with high prevalence 
of hepatitis B surface antigen (HBsAg) positive cases; 30% of the world’s HBsAg 
carriers are in China and 10% in India. Nevertheless, Nepal has a low prevalence 
(around 1%) of hepatitis B virus (HBV) infection in general population [6]. Hepatitis 
virus A and D genotypes are dominant in India, while Band C is dominant in China. 
The prevalence of HBV infection is low in Nepal, but still it is widely common among 
intravenous drug users, PLHA, and HCV-positive populations. Although our previous 
study revealed only A, D, and C/D recombinant genotype [8], in the locality of Nepal, 
all four common genotypes (A, B, C, and D) were reported in the previous study [7].
Phylogenetic tree (Figure 2) was obtained from the aligned sequences combining 
with all human hepatitis B subgenotypes. The Nepal 10 strain was a C/D recombinant 
genotype, and it is differed from the genotypes A and D or other Nepalese strains. 
Genotype A1 in Nepal was more similar to that of Bangladesh and the Philippines, 
while A2 was more similar to the genotype A2 of Japan, Germany, Canada, and Russia. 
Genotype A1 (Nepal 31, 41, 24, 64, 50, 6, 9, 7, 47 strains) is similar to the A1 genotype 
of the Philippines, while strain 36, 16, and 18 are more similar to Bangladesh A1 strain. 
Almost all A1 strains of Nepal showed 88% similarity with Malawi A1 strain. Basically, 
HBV E genotype of Ghana and Sweden is nearby the genotype D of Nepal. Even some 
sequences from Germany and Italy are similar to the genotype D of Nepal.
Among genotype D, Nepal 12 and 55 isolates are similar with German D geno-
type isolates, while Nepal 60 and 57 isolates are more similar with D isolates of Italy 
and France and Russian isolates of D genotype. These isolates are 93% similar with 
Nepal 21 f isolates from where the strain Nepal 28 was evolved. Nepal 28 isolates of 
D genotype is evolved to more similar isolates 22, 32, and 14. Nepal isolates 40, 38 
Figure 1. 
Global distribution of HBV genotype.
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1, 53, 11, 42, and 73 are more similar. Nepal 73 is more similar with 81, 79, and 72, 
while Nepal 81 and 79 is 88% similar with Nepal 72 isolates [8].
2. Clinical importance of HBV genotypes
As different regions have different serotypes and different clinical spectrum 
and different molecular epidemiological patterns, different HBV genotypes, but 
Figure 2. 
Phylogenetic tree of Nepal study 2012.
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not different rashes, may influence clinical outcome, HBeAg seroconversion rate, 
mutational patterns in the precore and core promoter regions, and response to 
interferon therapy [9].
Determination of genotypes: detection of the sequence differences in pre-S or 
S gene can be done by several methods, e.g., direct sequencing, restriction frag-
ment length polymorphism, line probe assay, genotype-specific PCR, and mass 
spectrometry.
3. Treatment: noncirrhotic patients
Cirrhosis is defined as distortion of the hepatic architecture and the formation 
of regenerative nodules. It is generally irreversible in its late stage. It can progress 
even to hepatocellular carcinoma (HCC). The recommendation for the treatment 
initiation for cirrhotic patients are available as three different guidelines (EASL 
2017, Asia pacific 2015, AASLD 2018) shown in Table 1 [4, 10, 11].
All patients with compensated cirrhosis HBeAg positive and HBV DNA 
level >20,000 U/ml with increased ALT twice higher than the normal limit are rec-
ommended to be treated by all three regional guidelines. However, AASLD guide-
line recommends different upper limit of normal (ULN) of ALT in male and female, 
i.e., 35 and 25, respectively, although EASL and APSL guidelines recommend 40 as 
ULN of ALT. HBeAg-negative patients with cirrhosis and HBV DNA > 2000 U/ml 
and the ALT twice higher than normal or the family history of cirrhosis and HCC 
are also recommended for treatment. EASL recommended to treat patients if fibro-
sis is present [10–12]. Different guideline recommendations are shown in Table 1.
4. Treatment: cirrhotic patients
Patients with compensated cirrhosis and HBV DNA level >2000 U/ml are treated 
per recommendations for immune-active chronic hepatitis B (CHB). All three guide-
lines recommend to treat patients with decompensated cirrhosis and detectable viral 
load. In cases of compensated cirrhosis, there is discrepancy among the guidelines. 
In cases of HBV DNA <2000 copy/ml, AASLD and EASL both recommend to treat 
irrespective to ALT, whereas APSL recommended to such cases to treat only when 
ALT is above normal [10–12]. Treatment guideline is shown in Table 2.
Guideline HBeAg positive HBeAg 
negative
ALT Family 
history
HBV 
DNA 
copies/
ml
ALT HBV 
DNA 
copies/
ml
Cirrhosis, 
HCC
EASL2017 >20,000 Double 
(40)
30 years >2000 Double + mod. 
fibrosis
Cirrhosis, 
HCC
Asia Pacific 
2015
>2000 Double 
(40)
>2000 Double
AASLD 
2018
>2000 Double 
(m/F 
35/25)
40 years >2000 Double Cirrhosis, 
HCC
Table 1. 
Comparison of the recommendation of different guideline treatments of noncirrhotic HBV patients.
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5. Clinical characteristics of different genotype are important
Genotype B is a common genotype in Asia. Some characteristics of genotype B 
are as follows [13–16]:
• Is commonly seen in young age less than 35 years as it is generally transmitted by 
perinatal or vertical route.
• The conversion from acute to chronic phase is less in this genotype.
• HBeAg seroconversion occurs earlier than genotype C.
• HBsAg seroclearance is faster than genotype C.
• Less patients develop cirrhosis.
• HCC development is less.
• Hepatic decompensation is less.
• HBV DNA is high in number.
• Less chance of getting fulminant hepatitis.
Genotype C is also a common genotype in Southeast Asia and China. 
Characteristics of genotype care are as follows [13–16]:
• Is commonly seen in young age less than 35 years generally transmitted by 
perinatal or vertical route.
• The conversion from acute to chronic phase is higher in this genotype.
• HBeAg seroconversion is less percentage and takes time than genotype B.
• HBsAg seroclearance is less than genotype B.
• High chance of getting cirrhosis.
• HCC development is more likely.
Guideline Compensated Decompensated ALT
HBV DNA 
copies/ml
ALT HBV DNA 
copies/ml
EASL 2017 If >2000 Irrespective Detectable Irrespective
Asia 
Pacific 
2015
>2000, if 
<2000
Detectable Irrespective
ASLD 
2018
2000 Irrespective Detectable Irrespective
Table 2. 
Comparison of the recommendation of treatment of different guideline of cirrhotic HBV patients.
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• Hepatic decompensation is higher in this genotype.
• HBV DNA is less in copy number.
• Less chance of getting fulminant hepatitis.
Genotype A is distributed worldwide. Characteristics of genotype A are as fol-
lows [13–16]:
• It is generally transmitted by horizontal route.
• The conversion from acute to chronic phase is frequent in this genotype.
• HBeAg seroconversion is earlier than genotype D.
• HBsAg seroclearance is also more frequent than genotype D.
• Less patients get cirrhosis.
• HCC development is less.
• Hepatic decompensation is higher.
• HBV DNA is high in copy number.
• Less chance of getting fulminant hepatitis.
Genotype 
clinical 
characteristics
B C A D E–J
Age Common <35 >35 — —
Modes of 
transmission
Perinatal/vertical Perinatal/
vertical
Horizontal Horizontal Horizontal
Chronicity Lower Higher Higher Lower —
HBeAg 
seroconversion
Earlier Later Earlier Later Earlier
HBeAg 
seroclearance
Earlier Later
HBsAg 
seroclearance
More Less More Less _
Cirrhosis Less active Active
HCC Better Worse Better Worse Worse in 
genotype F
HBV DNA level Higher Lower Higher Lower _
Hepatic 
decompensation
Lower Higher Higher Higher _
Fulminant 
hepatitis
Less Less Less Higher
Table 3. 
Clinical characteristics of different genotypes of HBV.
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Genotype D also has worldwide distribution. Characteristics of genotype D are 
as follows [13–16].
• Transmitted by horizontal route.
• The conversion from acute to chronic phase is less frequent in this genotype.
• HBeAg seroconversion takes longer time than genotype A.
• HBsAg seroclearance is less than genotype A.
• HCC development is most frequent.
• Hepatic decompensation is higher.
• HBV DNA is low in copy number.
• Higher chance of getting fulminant hepatitis.
Different HBV genotype clinical characteristics are compared in Table 3.
6. Antiviral treatment
The goal of therapy
• Decrease ALT—decrease necrotic inflammation in the liver
• Decrease viral load to the undetectable level
• HBeAg seroconversion to generate anti-HBeAg—to minimize the replication of virus
• To reduce HBsAg and seroconversion and anti-HBS
• Prevent development of new esophageal varices
Long-term goal is to reduce the risk of HCC and chronic liver diseases.
Peg-IFN alfa-2a or alfa-2b is recommended before starting peg-IFN therapy to 
HBeAg-positive patients; good responders should be identified; i.e., low viral load, 
HBV genotypes A and B, high serum ALT levels (above 2–5 times ULN) and high 
activity scores on liver biopsy are the predictors for better responding patients.
As the baseline predictor of response for the therapy to HBeAg-negative 
patient, HBV genotype, HBV DNA, ALT, HBsAg levels, and age are the crucial 
factors [17].
When to terminate Peg-IFN therapy: if low probability of response for HBeAg 
positive.
Or
No decline of HBsAg level for HBV genotype A and D at week 12 of treatment.
6.1 HBeAg loss
HBeAg loss with HBV DNA <2000 IU/ml for 6 months after treatment. 
Genotype D HBeAg-negative patient decreasing <2log decline in HBV DNA at week 
12 of peg-IFN therapy [18].
Hepatitis B and C
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Either entecavir or tenefovir is recommended for HIV
6.2 No response
HBeAg-positive patient with HBsAg level >20,000 IU/ml predicted no response 
after treatment. HIV positive, TNF + entecavir (lamivudine) + EFV is recom-
mended. Other drugs are recommended as the second-line therapy if the first-line 
drug treatment is failed (if HBV DNA > log10 IU/ml in 3-month period [19].
6.3 Response to lamivudine
Genotype B has sustain responsiveness to lamivudine followed by genotype C.  
Genotype A is more resistant than genotype D so that virological responses to the drug are 
better in genotype D than genotype A. Pediatric patients have good tolerance to lamivu-
dine. The younger the age at diagnosis, the longer consolidation treatment period [20].
6.4 Response to adefovirdipivoxil
Patients infected with genotypes A and D equally respond to 48-week treatment 
of adefovirdipivoxil, but there could be the adefovir resistance in patients having 
genotype D.
6.5 Response to entecavir or telbivudine
The relationship of HBV genotypes on drug resistance to entecavir was evaluated in 
lamivudine-refractory patients. Two-year therapy of telbivudine showed that HBeAg 
seroconversion, ALT normalization, and HBV negativity were comparable among 
different genotypes. Entecavir treatment has a chance of HBsAg seroloss in genotypes 
A and D, and the efficacy is better in Caucasian than in Asian population [20].
6.6 Tenefovir (TDF)
HBsAg loss in genotype A patient followed by genotype D (20 and 10%, 
respectively) was reported after completion of 144 weeks of treatment of TDF. The 
therapeutic effect was less in genotypes B and C [20].
Nucleotide 
analogue
Dose Adverse EASL ASL APSL
Lamivudine 100 mg/day Undetectable 
DNA
For 3 years
1–3 years 
after 
HBeAg-
negative 
patient
Undetectable 
DNA For 2 years
Adefovir 10 mg/day
Entecavir 0.5 mg/day
Telbivudine 600 mg/day
Tenofovir 300 mg/day Bone and 
renal 
impairment
Emcitrabine 200 mg/day
Tenofovir 
alafenamide
25 mg/day
Table 4. 
Antiviral treatment doses and period of recommendation by different guidelines.
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6.7 Management of incomplete responder
Incomplete responder should be checked for the drug adherence.
Patients who have previous exposure to lamivudine should be considered for 
entecavir resistance.
EASL recommend to switch to NA or combination therapy if detectable HBV 
DNA in 12 weeks of therapy. Combination of TDF + ETV has resulted in undetect-
able DNA even after 4 years, which is better than TDF alone [21]. Most of the study 
and the guideline do not recommend peg-IFN + nucleot(s)ide therapy, but recom-
mend to use peg-IFN after NA therapy. Antiviral drugs and their continuation 
recommended by different guideline are illustrated in Table 4.
7. Conclusion
HBV genotyping is important for the proper management of chronic HBV 
patients. Clinical characteristics may be helpful to estimate the genotype and initi-
ate antiviral therapy.
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